331 related articles for article (PubMed ID: 16740585)
1. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.
Dasbach EJ; Elbasha EH; Insinga RP
Epidemiol Rev; 2006; 28():88-100. PubMed ID: 16740585
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of male HPV vaccination in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
[TBL] [Abstract][Full Text] [Related]
4. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
5. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?
de Kok IM; Habbema JD; van Rosmalen J; van Ballegooijen M
Eur J Cancer; 2011 Feb; 47(3):428-35. PubMed ID: 20971633
[TBL] [Abstract][Full Text] [Related]
6. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
[TBL] [Abstract][Full Text] [Related]
7. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
[TBL] [Abstract][Full Text] [Related]
9. Cost–effectiveness of catch-up programs in human papillomavirus vaccination.
de Peuter MA; Littlewood KJ; Annemans L; Largeron N; Quilici S
Expert Rev Vaccines; 2010 Oct; 9(10):1187-201. PubMed ID: 20923269
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
Bergeron C; Largeron N; McAllister R; Mathevet P; Remy V
Int J Technol Assess Health Care; 2008; 24(1):10-9. PubMed ID: 18218164
[TBL] [Abstract][Full Text] [Related]
11. Prevention strategies against human papillomavirus in males.
Garland SM
Gynecol Oncol; 2010 May; 117(2 Suppl):S20-5. PubMed ID: 20138347
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of human papilloma virus vaccination in Iceland.
Oddsson K; Johannsson J; Asgeirsdottir TL; Gudnason T
Acta Obstet Gynecol Scand; 2009; 88(12):1411-6. PubMed ID: 19900074
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of human papillomavirus vaccination in developed countries.
Brisson M; Van de Velde N; Boily MC
Public Health Genomics; 2009; 12(5-6):343-51. PubMed ID: 19684446
[TBL] [Abstract][Full Text] [Related]
14. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
15. Anti-HPV vaccination: a review of recent economic data for Italy.
Mennini FS; Costa S; Favato G; Picardo M
Vaccine; 2009 May; 27 Suppl 1():A54-61. PubMed ID: 19480963
[TBL] [Abstract][Full Text] [Related]
16. Vaccines for preventing HPV-related anogenital infection and neoplasia.
Ferris DG
J Am Osteopath Assoc; 2006 Mar; 106(3 Suppl 1):S9-13. PubMed ID: 16729555
[TBL] [Abstract][Full Text] [Related]
17. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
Dunne EF; Datta SD; E Markowitz L
Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
[TBL] [Abstract][Full Text] [Related]
18. The epidemiology behind the HPV vaccine discovery.
Koutsky L
Ann Epidemiol; 2009 Apr; 19(4):239-44. PubMed ID: 19344861
[TBL] [Abstract][Full Text] [Related]
19. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.
Syrjänen KJ
Scand J Infect Dis Suppl; 2009; 107():3-32. PubMed ID: 19408160
[TBL] [Abstract][Full Text] [Related]
20. Mathematical models of cervical cancer prevention in the Asia Pacific region.
Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]